News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
MethylGene Selects Histone Deacetylase Antifungal Clinical Candidate
May 17, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MONTREAL, QUEBEC -- (MARKET WIRE) -- May 17, 2007 -- MethylGene Inc. (TSX: MYG), today announced the selection of MGCD290 as the clinical candidate emanating from its histone deacetylase (HDAC) antifungal program.
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
MORE ON THIS TOPIC
Cardiovascular disease
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
July 10, 2026
·
3 min read
·
Tristan Manalac
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
July 10, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
July 9, 2026
·
2 min read
·
Nick Paul Taylor
Cardiovascular disease
AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3
July 9, 2026
·
3 min read
·
Tristan Manalac
